Abstract
The expression of the erbB2 and p53 proteins was examined by immunohistochemistry in a series of 81 cases of primary breast carcinomas treated with an adjuvant chemotherapy with a median follow-up of 5 years. Expression of erbB2 was present in 19 cases (23%), 50% of them with more than 70% of positive tumoral cells. Expression of p53 was present in 32 cases (39%), 50% of them with more than 30% of positive tumoral cells; coexpression of erbB2 and p53 was observed in 11 cases (13.5%). Disease-free and overall survival of the patients were correlated with the number of positive lymph nodes (p = 0.08, p = 0.015). No significant trend was observed in response to adjuvant chemotherapy in correlation with erbB2 or p53 expression or both, whatever the level of expression.
Publication types
-
Clinical Trial
-
Comparative Study
-
Controlled Clinical Trial
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Adult
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
-
Biomarkers, Tumor / analysis
-
Breast Neoplasms / drug therapy*
-
Breast Neoplasms / metabolism
-
Breast Neoplasms / pathology
-
Breast Neoplasms / therapy
-
Chemotherapy, Adjuvant*
-
Cisplatin / administration & dosage
-
Female
-
Fluorouracil / administration & dosage
-
Gene Expression
-
Humans
-
Immunohistochemistry
-
Methotrexate / administration & dosage
-
Middle Aged
-
Mitoxantrone / therapeutic use
-
Ovariectomy
-
Predictive Value of Tests
-
Prognosis
-
Receptor, ErbB-2 / analysis
-
Receptor, ErbB-2 / biosynthesis*
-
Tamoxifen / therapeutic use
-
Tumor Suppressor Protein p53 / analysis
-
Tumor Suppressor Protein p53 / biosynthesis*
Substances
-
Biomarkers, Tumor
-
Tumor Suppressor Protein p53
-
Tamoxifen
-
Mitoxantrone
-
Receptor, ErbB-2
-
Cisplatin
-
Fluorouracil
-
Methotrexate